A Potential New Use for Tocilizumab: Refractory Checkpoint Inhibitor Hepatitis
Laine Lyles, Reagan Farmer, Marwan S. Abougergi
Abstract
Immune checkpoint inhibitors are becoming more commonly used for many forms of malignancy. With this class of medications being more heavily used, there has been an associated rise in medication-induced autoimmune hepatitis. This case involves a 35-year-old woman being treated with nivolumab/ipilimumab for renal cell carcinoma who developed a steroid-refractory autoimmune hepatitis.
Topics & Concepts
MedicineNivolumabIpilimumabTocilizumabRefractory (planetary science)Autoimmune hepatitisMalignancyHepatitisImmunologyOncologyInternal medicineCancerImmunotherapyRheumatoid arthritisAstrobiologyPhysicsCancer Immunotherapy and BiomarkersChronic Lymphocytic Leukemia ResearchHepatocellular Carcinoma Treatment and Prognosis